Product Information
NEOMYCIN-POLYMYXIN-HC EAR SUSP is a generic product labeled by Rising Pharma Holdings Inc., priced at $3.7894 per ML under NDC 64980044801. Its NADAC has been published 311 times since Sep 9, 2020.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AT.
NEOMYCIN-POLYMYXIN-HC EAR SUSP
neomycin and polymyxin B sulfates and hydrocortisone oticStrength
10; 3.5; 10000 mg/mL; mg/mL; [USP'U]/mL
Manufacturer
Rising Pharma Holdings Inc.NDC
64980044801
Classification
Generic
Dosage Form
SUSPENSION
Route
AURICULAR (OTIC)
Effective Date
8/19/2026
Active Ingredients
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA060613FDA Approved
Before 1982
TE Code
AT
On Market Since
3/15/2019
Pharmacological Classes
Price Statistics
The NADAC for NEOMYCIN-POLYMYXIN-HC EAR SUSP has been published 311 times since Sep 9, 2020, and over the history we have for it it has declined 35.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.7894 per ML |
|---|---|
| All-time high | $6.3337 (May 11, 2022) |
| All-time low | $3.7744 (Jul 22, 2026) |
| 52-week high | $4.6405 |
| 52-week low | $3.7744 |
| Median price | $5.3738 |
| Average price | $5.1797 |
| Largest weekly change | +39.2% (Aug 21, 2024) |
| Weeks tracked | 311 |
| Tracking since | Sep 9, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the neomycin and polymyxin B sulfates and hydrocortisone otic market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of NEOMYCIN-POLYMYXIN-HC EAR SUSP?
The current National Average Drug Acquisition Cost (NADAC) for NEOMYCIN-POLYMYXIN-HC EAR SUSP, manufactured by Rising Pharma Holdings Inc., is $3.7894 per ML (NDC 64980044801), effective Aug 19, 2026.
How has the price of NEOMYCIN-POLYMYXIN-HC EAR SUSP changed over time?
Over the history we have for it, the NADAC for NEOMYCIN-POLYMYXIN-HC EAR SUSP has declined 35.1%. It has been tracked across 311 weekly CMS publications since Sep 9, 2020.
What are the highest and lowest recorded NADAC prices for NEOMYCIN-POLYMYXIN-HC EAR SUSP?
Since Sep 9, 2020, the NADAC for NEOMYCIN-POLYMYXIN-HC EAR SUSP has ranged from a low of $3.7744 (Jul 22, 2026) to a high of $6.3337 (May 11, 2022), with a median of $5.3738 per ML.
Are there cheaper alternatives to NEOMYCIN-POLYMYXIN-HC EAR SUSP?
No other NADAC-published product currently shares the active ingredient and strength of NEOMYCIN-POLYMYXIN-HC EAR SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEOMYCIN-POLYMYXIN-HC EAR SUSP?
NEOMYCIN-POLYMYXIN-HC EAR SUSP (NDC 64980044801) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.